ReviewIndian journal of pharmacology
Endocan: a novel circulating proteoglycan.
Review in Indian journal of pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 149 citations in OpenAlex.
- High circulating endocan in chronic kidney disease? A systematic review and meta-analysis.PloS one · 2023Pooled it
- The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: A meta-analysis.Medicine · 2018Pooled it
- Endocan Participates in TGF-β/Smad and AKT/ERK Signaling Coordination and lncRNA Modulation in Human Cardiac Fibroblasts.International journal of molecular sciences · 2026Article
- The Influence of Statin Therapy on Markers of Endothelial Dysfunction, Endocan and Endoglin, in Postmenopausal Women-A Prospective Study.Biomedicines · 2026Article
- Endothelial Cell-Specific Molecule-1 (ESM1): An Endogenous Anticoagulant and Protective Factor in Venous Thrombosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Evaluation of Serum Endocan and Testosterone Levels in Male Patients with Prediabetes: A Cross-Sectional Clinical Study.Journal of clinical medicine · 2026Article
- Immune-mediated skin diseases and erectile dysfunction: mechanisms and multidisciplinary management.Frontiers in immunology · 2026Review
- Circulating and Respiratory Biomarkers in Sepsis-Induced ARDS: Diagnostic and Prognostic Insights - A Narrative Review.Journal of inflammation research · 2026Review
- Relationship Between Carotid Intima-Media Thickness, Serum Endocan and Hyaluronic Acid Levels in Multiple Sclerosis.Life (Basel, Switzerland) · 2025Article
- Serum Endocan Levels Correlate with Metabolic Syndrome Severity and Endothelial Dysfunction: A Cross-Sectional Study Using the MetS-Z Score.Metabolites · 2025Article
- Evaluation of prognostic value of vascular endothelial growth factor and endocan in non-small cell lung cancer.Turkish journal of medical sciences · 2025Article
- Endocan as a biomarker for acute respiratory distress syndrome: A systematic review and meta-analysis.Health science reports · 2024Review
- Article
- Roles of endothelial cell specific molecule‑1 in tumor angiogenesis (Review).Oncology letters · 2024Review
- Endocan, a novel glycoprotein with multiple biological activities, may play important roles in neurological diseases.Frontiers in aging neuroscience · 2024Review
- Relationship between angiogenesis biomarker endocan and apolipoproteins in patients with acute myocardial infarction.Future cardiology · 2024Article
- Association between serum endocan levels and organ failure in hospitalized patients with cirrhosis.PloS one · 2024Article
- Article
- Endocan as a Potential Marker for Predicting All-Cause Mortality in Hemodialysis Patients.Journal of clinical medicine · 2023Article
- Early Diagnostic Markers of Late-Onset Neonatal Sepsis.Pediatric reports · 2023Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endocan is a novel endothelium derived soluble dermatan sulfate proteoglycan. It has the property of binding to a wide range of bioactive molecules associated with cellular signaling and adhesion and thus regulating proliferation, differentiation, migration, and adhesion of different cell types in health and disease. An increase in tissue expression or serum level of endocan reflects endothelial activation and neovascularization which are prominent pathophysiological changes associated with inflammation and tumor progression. Consequently, endocan has been used as a blood-based and tissue-based biomarker for various cancers and inflammation and has shown promising results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.